Literature DB >> 33831910

A decision analytics model to optimize investment in interventions targeting the HIV preexposure prophylaxis cascade of care.

Samuel M Jenness1, Gregory Knowlton2, Dawn K Smith3, Julia L Marcus4, Emeli J Anderson1, Aaron J Siegler1, Jeb Jones1, Patrick S Sullivan1, Eva Enns2.   

Abstract

OBJECTIVES: Gaps between recommended and actual levels of HIV preexposure prophylaxis (PrEP) use remain among MSM. Interventions can address these gaps but it is unknown how public health initiatives should invest prevention funds into these interventions to maximize their population impact.
DESIGN: We used a stochastic network-based HIV transmission model for MSM in the Atlanta area paired with an economic budget optimization model.
METHODS: The model simulated MSM participating in up to three real-world PrEP cascade interventions designed to improve initiation, adherence, or persistence. The primary outcome was infections averted over 10 years. The budget optimization model identified the investment combination under different budgets that maximized this outcome, given intervention costs from a payer perspective.
RESULTS: From the base 15% PrEP coverage level, the three interventions could increase coverage to 27%, resulting in 12.3% of infections averted over 10 years. Uptake of each intervention was interdependent: maximal use of the adherence and persistence interventions depended on new PrEP users generated by the initiation intervention. As the budget increased, optimal investment involved a mixture of the initiation and persistence interventions but not the adherence intervention. If adherence intervention costs were halved, the optimal investment was roughly equal across interventions.
CONCLUSION: Investments into the PrEP cascade through initiatives should account for the interactions of the interventions as they are collectively deployed. Given current intervention efficacy estimates, the total population impact of each intervention may be improved with greater total budgets or reduced intervention costs.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33831910      PMCID: PMC8243826          DOI: 10.1097/QAD.0000000000002909

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  1 in total

1.  A Pilot Study of a Patient Navigation Intervention to Improve HIV Pre-exposure Prophylaxis Persistence Among Black/African American Men Who Have Sex With Men.

Authors:  William C Goedel; Cassandra Sutten Coats; Philip A Chan; Courtney E Sims-Gomillia; James B Brock; Lori M Ward; Leandro A Mena; Amy S Nunn
Journal:  J Acquir Immune Defic Syndr       Date:  2022-07-01       Impact factor: 3.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.